University College London  

UCL  United Kingdom
  Gower Street, London, WC1E 6BT UCL  
Principal Investigator(s):
  Prof. Sébastien Ourselin / Prof. Yiannis Ventikos


List of researchers and collaborators involved in the project:

  Dr. David M Cash
Mr. Dean Chou
Prof. Sébastien Ourselin
Mr. John Vardakis
Prof. Yiannis Ventikos
  WP3 Data Access & Disease Biomarkers from Large-scale Population Studies
WP6 Multiscale Phenomenological Modelling: Clinical & Environment Factors
WP7 Biomedical Research Platform for Disease Modelling and Model Personalization
Main competencies:
The Centre for Medical Image Computing (CMIC) from University College London (UCL) combines excellence in medical imaging with innovative computational methodology, with a focus on translating techniques into clinical use and a particular interest in neuro-degenerative dementia. CMIC is a multi-disciplinary centre hosting 60 researchers focusing on medical image processing. The centre has strong links with hospitals and more specifically with the National Hospital for Neurology and Neurosurgery. Researchers at CMIC have pioneered novel, automated and highly accurate methods for combining and comparing image-derived information. These methods have been applied to multiple cohorts of patient affected with neuro-degenerative diseases through a close collaboration with the Dementia Research Centre (Institute of Neurology, UCL).

Contributions to the project
The Centre for Medical image Computing (CMIC) has a good track record of developing and translating imaging biomarkers for neuro-degenerative studies. These biomarkers include, but are not limited to, global or local atrophy measurement to quantify temporal changes, efficient methods for global and local image alignment, brain tissue segmentation and cortical thickness or folding pattern extraction and analysis. All methods developed at CMIC are integrated into a common software environment, named NifTK. This software package enables easy translation to clinical partners such as the Dementia Research Centre. As a result, the methodologies developed at CMIC are currently routinely used for large clinical studies and large phase II-III clinical trials for neuro-denegenerative drug validation. All these tools and the associated expertise will contribute directly to the success of WP3, 6 and 7.